Introduction
============

Breast cancer remains one of the leading causes of cancer death among women despite the huge progress that has been made in treatment ([@bib27], [@bib32]). Many risk factors for postmenopausal breast cancer are suggested to mediate their effect through a hormonal mechanism ([@bib11]). The largest meta-analysis combining nine prospective studies demonstrated that postmenopausal women with serum estrogen and androgen levels in the highest quintiles have a twofold increased risk of breast cancer ([@bib14]). Since then, a number of studies have reported conflicting results on the association of serum sex steroid hormones and breast cancer risk ([@bib16], [@bib20], [@bib24], [@bib23], [@bib35], [@bib36], [@bib12], [@bib30], [@bib1], [@bib4], [@bib8], [@bib28], [@bib3]). All these reports have used conventional immunoassays to measure hormone levels. In the past few years, bioactivity assays for steroid hormone receptors have been described, enabling quantification of total hormone action ([@bib25], [@bib29], [@bib26]). As estrogen and androgen hormones exert their effects through binding to sex steroid hormone receptors, we previously hypothesized that bioactivity assays might be an attractive alternative for breast cancer risk assessment. We found that estrogen receptor α (ERα) and ERβ serum bioactivity (SB) are independently associated with breast cancer using samples collected at diagnosis ([@bib33]).

To better understand the long-term effect of sex steroids and bioactivity of their receptors on breast cancer risk, it is crucial to examine levels many years before diagnosis. We were able to explore this issue using the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS) biobank. Women recruited to the trial between 2001 and 2005 provided blood samples for secondary studies and continue to be followed up by cancer registration and self-reporting ([@bib21], [@bib22]). We report on a nested case--control study using serum samples donated between 6 months and 5 years before diagnosis by women who developed breast cancer after joining the trial and healthy women who had not developed the disease. SB of ERα and ERβ and androgen receptor (AR) were measured using a yeast-based assay along with five sex steroid hormones (estradiol (E~2~), estrone, androstenedione, testosterone, and dehydroepiandrosterone sulfate (DHEAS)), free E~2~ (fE~2~) and free testosterone (fT; calculated by the mass action law), and sex hormone-binding globulin (SHBG) using conventional immunoassays to examine their association with breast cancer risk.

Materials and methods
=====================

Cohort
------

The subjects were participants in the UKCTOCS, a multicenter randomized controlled trial of ovarian cancer screening in England, Wales, and Northern Ireland, coordinated by the Gynecological Cancer Research Centre at University College London (UCL). Women aged 50--74 were recruited through random invitation from age/sex registers of 27 participating Primary Care Trusts. At recruitment, each woman donated a blood sample, filled in a baseline questionnaire, and provided written consent giving permission to access their medical records and use their data/samples in future studies. The questionnaire included questions on demographics, height, weight, parity, hysterectomy, tubal ligation, treatment for infertility, contraceptive pill, hormone replacement treatment (HRT), and previous history of any cancer and family history of ovarian/breast cancer ([@bib21]).

Selection of the study sample
-----------------------------

All participants are being followed up through a 'flagging study' with the NHS Information Centre for Health and Social Care. Up-to-date cancer registration data were obtained from the agencies on 2nd February 2009 (median follow-up 5.681 years and interquartile range (IQR), 1.284 years). For confirmation of diagnosis, their treating physician was sent a questionnaire requesting information regarding their diagnosis (histology) and treatment. Two hundred women who developed ER-positive invasive breast cancer after joining the UKCTOCS and were not on HRT treatment at recruitment and had donated a serum sample between 6 months and 5 years before diagnosis were chosen as 'cases' for this study. Each breast cancer case was age matched with two women who had no history of breast cancer (controls) at last follow-up and had donated serum samples on the same day and in the same clinic. The UKCTOCS was approved by the UK North West Multicentre Research Ethics Committees (North West MREC 00/8/34). Ethical approval for this nested case--control study was obtained from the Joint UCL/UCLH Committees on the Ethics of Human Research (22nd February 2007, 06/Q0505/102).

Serum sample processing
-----------------------

The blood samples were collected into Griener Bio one gel tubes (Cat no: 455071) at the centers, shipped overnight to the central laboratory, and centrifuged at 2000 ***g*** for 10 min. The serum was removed from the cells within 56 h of sample collection and was frozen using a two-stage freezing process: 12 h at −80 °C and then placed in liquid nitrogen (vapor phase) at −180 °C. A novel semi-automated system aliquoted serum in 500 μl straws was then heat sealed, bar coded, data based, and stored in liquid nitrogen tanks. Two straws were retrieved, one for the measurement of hormone levels and one for the bioactivity assays. The samples were only thawed once, at the time of the assay.

Sex steroid hormone receptor bioactivity using bioassay systems
---------------------------------------------------------------

Sex steroid hormone receptor bioactivity was measured using a yeast-based reporter gene assay that not only determines whether a chemical binds to the receptor, but also whether estrogen- or androgen-dependent gene expression is stimulated. The assay has been described previously ([@bib33]). Briefly, the genetically modified yeast cells were incubated in a defined test medium with the reference substance E~2~ for ERα and ERβ and dihydrotestosterone for AR test samples and negative controls. At the end of the incubation period the developed green fluorescence was determined and corrected for cell density, optical density (OD) of the cell suspension and blanks. The cell growth was determined by measuring the light absorption at 600 nm and GFP-fluorescence by measuring GFP at 535 nm, specific OD and fluorescence at *t*=0 and *t*=16.5 h for ERα and ERβ and *t*=24 h for AR in each of the 96 wells. Tests were considered as valid if the turbidity of the negative control culture increased five times during the incubation period. The control culture showed no fluorescence. The bioactivity was determined by comparison of the fluorescence development in test cultures vs the calibration curve. The dose--response curves of the reference values were fitted using the Hill equation fit and the R-function. The analysis was performed blind and cases and controls were randomly mixed. Tests were carried out with two replicates at a time on two different days (four readings in total). The lower detection limit for the ER SB is 5 pg/ml and for AR SB is 0.2 ng/ml. The inter-assay coefficients of variation were lower than 20%.

Hormone levels using immunoassay systems
----------------------------------------

For E~2~, testosterone, DHEAS, and SHBG kits were obtained from Roche and the samples were run on an Elecsys 2010 analyzer (Roche Diagnostics GmbH). Androstenedione levels were measured using an ELISA kit on DPC IMMULITE 2500 analyzer (Siemens Medical Solutions Diagnostics, Munich, Germany). For estrone ELISA kit was obtained from DRG (DRG Instruments GmbH, Marburg, Germany). The samples were analyzed blind and cases and controls were randomly mixed in batches using a single lot number of reagent and calibrator. One scientist did all the measurements. Two levels of quality control (QC) material were analyzed with each run on the analyzer and standard Westgard rules applied. Two levels of QC material were included on each plate for the manual ELISA assays. FE~2~ and fT were calculated using the equation based on the law of mass action ([@bib31]).

Statistical analysis
--------------------

Mean and median levels of sex steroid hormones, ERα and ERβ and AR SB were calculated for all breast cancer samples and controls. Differences in the medians between the groups were tested for statistical significance using the Kruskal--Wallis test. Correlations between sex steroid hormones, and ERα and ERβ and AR SB among cases and controls were assessed by the Spearman\'s rank correlation coefficient. Subjects were classified according to quintiles of the respective marker among controls. The associations between ERα, ERβ, AR SB, hormone levels and the risk of breast cancer were determined by logistic regression analysis controlling for age. Finally, SB levels of each receptor were controlled for all hormones and SB in regression models to estimate their independent associations with breast cancer risk.

Results
=======

The median age of the 200 women with breast cancer (cases) was 61.33 (IQR, 11.32) and 62.33 (IQR, 9.57), in the 400 healthy women (matched controls). Breast tumor characteristics of the cases were similar to a typical breast cancer cohort ([Table 1](#tbl1){ref-type="table"}). None of the traditional risk factors (family history, age at menarche, menopause, number of pregnancies, contraceptive pill use, hysterectomy, infertility, body mass index, and height) were significantly different between cases and controls except for fallopian tube ligation (odds ratio (OR) for breast cancer, 0.57; 95% confidence interval (CI), 0.35--0.94; *P*=0.029).

Using all samples, correlations of sex steroid hormones and SHBG with sex steroid receptor SB were investigated. FE~2~ and fT showed a statistical significant positive correlation and SHBG a negative correlation with ERα, ERβ, and AR SB. All three sex steroid hormone receptor SB correlated with each other ([Table 2](#tbl2){ref-type="table"}).

For the purposes of the analysis, women were stratified into groups based on whether their sample was obtained 6 months to ≤2 or \>2--5 years before breast cancer diagnosis. We decided to use the same cut off as that used in the largest reanalysis by [@bib14] that included nine prospective studies. For those women who had given a sample \>2 years before diagnosis, the serum androgens: androstenedione, testosterone, and fT, and both ERα and ERβ SB showed significant differences between cases and controls ([Table 3](#tbl3){ref-type="table"}). We further analyzed the data based on quintiles with subjects being classified according to quintiles of the respective marker among controls. Women with serum ERα bioactivity in the top quintile had a 2.15 (95% CI, 1.05--4.43; *P*\<0.05)-fold breast cancer risk ([Table 4](#tbl4){ref-type="table"}). No association was shown between breast cancer risk and ERβ and AR SB ([Table 4](#tbl4){ref-type="table"}). Women with serum levels in the top quintile of androstenedione, testosterone, and fT were significantly associated with 4.36 (95% CI, 1.87--11.55)-, 2.53 (95% CI, 1.24--5.41)-, and 2.84 (95% CI, 1.30--6.64)-fold risk for breast cancer respectively ([Table 4](#tbl4){ref-type="table"}). Other hormones tested did not show any significant association with breast cancer risk ([Table 4](#tbl4){ref-type="table"}). To test whether serum sex steroid receptor bioactivity is independently associated with breast cancer logistic regression analysis was performed adjusting for all hormones and SB. ERα bioactivity was independently associated with breast cancer after adjustment for all hormones and AR and borderline significant after adjustment for ERβ for those women who had given a sample \>2 years before diagnosis. Furthermore, after adjustment for all hormones and SB both androstenedione and testosterone were independently associated with breast cancer risk (data not shown).

For those women who had given samples ≤2 years before diagnosis, ERα, ERβ, and AR SB did not show any significant association with breast cancer and did not predict risk ([Tables 3](#tbl3){ref-type="table"} and [4](#tbl4){ref-type="table"}). This observation did not change after adjusting for all hormones and SB. SHBG and serum fT showed significant differences between cases and controls ([Table 3](#tbl3){ref-type="table"}). Serum levels in the top quintile of androstenedione, testosterone, fT, and estrone were significantly associated with 2.49 (95% CI, 1.20--5.46)-, 1.870 (95% CI, 0.97--3.70)-, 2.02 (95% CI, 0.09--4.24)-, and 2.21 (95% CI, 1.10--4.59)-fold risk for breast cancer respectively ([Table 4](#tbl4){ref-type="table"}). The association of androstenedione, testosterone, and estrone with breast cancer risk remained statistically significant after adjustment for all hormones and SB (data not shown). In addition, women who had serum levels in the top quintile of SHBG had a reduced risk of breast cancer (0.32; 95% CI, 0.13--0.73; *P*=0.001; [Table 4](#tbl4){ref-type="table"}). Other hormones tested did not show any significant association with breast cancer risk ([Table 4](#tbl4){ref-type="table"}).

Analysis was also undertaken combining both groups. For the 11 hormones and sex steroid receptor SB, differences between cases and controls were observed for serum androstenedione, testosterone, and fT levels ([Table 3](#tbl3){ref-type="table"}). ERα, ERβ, and AR SB did not show any significant association with breast cancer and did not predict risk ([Table 4](#tbl4){ref-type="table"}). This observation did not change after adjusting for all hormones and SB. Women who had serum levels in the top quintile of androstenedione, testosterone, and fT had 3.187 (95% CI, 1.74--6.04)-, 2.15 (95% CI, 1.26--3.71)-, and 2.35 (95% CI, 1.33--4.26)-fold breast cancer risk respectively ([Table 4](#tbl4){ref-type="table"}). The association of androstenedione and testosterone with breast cancer risk remained statistically significant after adjustment for all hormones and SB (data not shown). Other hormones examined did not show any significant association with breast cancer risk ([Table 4](#tbl4){ref-type="table"}).

Discussion
==========

The study adds to the ongoing effort to better understand the association of sex steroid hormones with breast cancer. This report is the first we are aware of that examines the role of sex steroid hormone receptor bioactivity using a yeast-based bioassay and sex steroid hormones using conventional immunoassays before breast cancer diagnosis within a well-defined cohort of women diagnosed with estrogen-sensitive breast cancer and healthy controls. Serum ERα and ERβ were significantly higher in postmenopausal women before diagnosis, with women having a twofold increased breast cancer risk if ERα SB was in the top quintile more than 2 years before diagnosis. Estrogens were not found to be significantly different between cases and controls but women with estrone levels in the top quintile \<2 years before diagnosis had a twofold increased breast cancer risk. Testosterone and androstenedione were significantly higher among cases compared with controls and showed a strong association with an almost threefold increased breast cancer risk independent of time to diagnosis. However, this was not reflected in serum AR bioactivity that was not associated with breast cancer.

The strengths of this study are 1) the nested case--control design within a well-defined cohort with prospective identification of breast cancer cases, 2) use of standardized protocol for serum sample collection and storage with protocol adherence confirmed by the lack of any difference in mean hormone or steroid receptor SB levels between the different trial centers (data not shown), 3) confirmation of breast cancer diagnosis and receptor status from the treating physicians that eliminated possible misidentification of cases from use of cancer registry data or self-reporting alone, 4) well-defined homogenous cases through use of strict eligibility criteria (women not on HRT with ER-positive invasive breast cancer), and 5) selection of controls from the same population as those with breast cancer.

Our observations that ERα and ERβ SB were significantly higher in postmenopausal women before diagnosis of invasive ER-positive breast cancer extend our previous findings of elevated bioactivity in women with breast cancer at the time of clinical diagnosis ([@bib33]). The receptor SB showed statistically significant correlation with fE~2~ that has the highest known affinity for ERα ([@bib17]). This is in keeping with the meta-analysis results that women with high E~2~ levels more than 2 years before diagnosis had a higher breast cancer risk compared with those who had high E~2~ levels closer to diagnosis ([@bib14]). Serum receptor activation is probably modulated by other surrogates as well. In our previous study, receptor SB was two- to threefold higher than the actual E~2~ concentration ([@bib33]). This may explain the increased breast cancer risk in women with ERα SB in the highest quintile more than 2 years before diagnosis in the absence of a correlation with individual estrogens. The potential advantage of using SB assays for steroid receptors is that their levels reflect the sum of all the factors in the serum that transactivate the two different ERs. Furthermore, previous data based on cell-based assays have shown ERβ to be less active on gene transcription than ERα ([@bib10]). This could explain our findings that while ERβ SB is different among cases and controls, levels in the top quintile are not associated with an increased breast cancer risk.

Lack of association between E~2~ and breast cancer risk may also be attributed to the assay performance. E~2~ levels in postmenopausal women are very low and over the last few years there have been concerns about the sensitivity of direct immunoassays to measure such hormones ([@bib27]). Estrone (the main circulating estrogen in postmenopausal women) in the top quintile was associated with increased risk 2 years before breast cancer diagnosis. This observation of estrone rather than E~2~ having a stronger association with increased breast cancer risk has been reported by other authors ([@bib35]). After adjustment for all the other hormones and SB, estrone remained associated with breast cancer risk indicating an independent role. It has weak and low affinity to ERα ([@bib5]) and may exert its effect on breast carcinogenesis by inducing ERK phosphorylation via binding to the estrogen G protein-coupled receptor 30 (GPR30; [@bib19], [@bib34]). If a significant ER-independent pathway is confirmed, it could have implications for hormone therapy in prevention and treatment of breast cancer in postmenopausal women.

Androstenedione and testosterone were associated with an almost threefold increase in breast cancer risk independent of time from diagnosis. The meta-analysis of nine studies in postmenopausal women confirmed that high testosterone and androstenedione levels were associated with increased risk ([@bib14]). The more recent report from EPIC ([@bib12]) also confirmed that androgens were associated with breast risk independent of time to diagnosis. After adjustment for estrogens, the association of the androgens with breast cancer risk remained, indicating that they may have an estrogen-independent effect on the breast, an observation that has been reported by other authors ([@bib14], [@bib23], [@bib12]). One of the possible pathways that androgens may influence breast cancer risk is by directly binding to AR, stimulating or inhibiting breast cell growth ([@bib18], [@bib6]) but we were unable to demonstrate such an association. While fT is the best ligand of AR, androgens have also been shown to bind and activate ERs ([@bib18]). Our data showing a statistically significant correlation between fT and both ERs favor the view for the existence of the latter pathway where androgens promote breast cell proliferation by binding directly to ER.

To summarize, our findings provide further evidence of the association between sex steroid hormones and breast cancer risk. Testosterone and estrone were shown to be associated with increased breast cancer risk. Based on that, it would be interesting to evaluate the association of key enzymes in steroidogenesis such as aromatase and 17β-hydroxysteroid dehydrogenases and breast cancer. In addition, our report provides novel insight into the role of sex steroid receptor SB in breast cancer with ER but not AR SB associated with increased risk more than 2 years before diagnosis. Further development of these assays might appear promising for giving greater insight into the role of sex hormones in relation to breast cancer risk but on the basis of the current results the assays do not appear to have a stronger association with breast cancer risk compared with this and previous studies using conventional assays. If ER SB results are validated in other studies, it may also prove beneficial in individualizing and monitoring breast cancer chemopreventive strategies using antiestrogens such as tamoxifen ([@bib7]), raloxifene ([@bib9]), and aromatase inhibitors ([@bib13]).
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###### 

Characteristics of the breast cancer cases

                               **No.**
  ---------------------------- ---------
  Histology                    
   Ductal                      156
   Ductal and lobular          6
   Lobular                     25
   Mucinous                    1
   NST                         3
   Tubular                     1
   Other                       8
  Stage                        
   1                           96
   2                           39
   3                           10
   Unknown                     55
  Grading                      
   1                           32
   2                           111
   3                           53
   Unknown                     4
  Estrogen receptor (ER)       
   ER-positive                 200
  Progesterone receptor (PR)   
   PR-negative                 32
   PR-positive                 100
   Unknown                     68
  HER2                         
   HER2-negative               79
   HER2-positive               16
   Unknown                     105

NST, no specified type; HER2, human epidermal growth factor receptor 2.

###### 

Spearman\'s correlation coefficients among estrogens, androgens, SHBG, and serum bioactivity of estrogen and androgen receptors for cases and controls combined

                      **Correlation coefficients**                                                   
  ------------------- ------------------------------ --------------- --------------- --------------- -----
  Estradiol (E~2~)    0.059                          0.062           0.055           0.313           573
                      *P*=0.181                      *P*=0.16        *P*=0.214       ***P*=0.000**   
  Free E~2~           0.124                          0.148           0.109           0.444           555
                      ***P*=0.005**                  ***P*=0.001**   ***P*=0.013**   ***P*=0.000**   
  Estrone             0.025                          0.066           0.080           0.098           582
                      *P*=0.565                      *P*=0.132       *P*=0.067       ***P*=0.021**   
  Androstenedione     0.058                          0.081           0.002           0.097           581
                      *P*=0.186                      *P*=0.064       *P*=0.963       ***P*=0.022**   
  Testosterone        0.024                          0.051           0.034           0.132           575
                      *P*=0.592                      *P*=0.244       *P*=0.443       ***P*=0.001**   
  Free testosterone   0.102                          0.139           0.090           0.545           558
                      ***P*=0.021**                  ***P*=0.002**   ***P*=0.041**   ***P*=0.000**   
  DHEAS               0.020                          0.010           0.012           0.010           580
                      *P*=0.647                      *P*=0.814       *P*=0.785       *P*=0.803       
  SHBG                −0.220                         −0.242          −0.128          −0.423          580
                      ***P*=0.005**                  ***P*=0.000**   ***P*=0.004**   ***P*=0.000**   
  ERα                                                0.507           0.307           0.074           588
                                                     ***P*=0.000**   ***P*=0.000**   *P*=0.073       
  ERβ                 0.507                                          0.330           0.126           589
                      ***P*=0.000**                                  ***P*=0.000**   ***P*=0.002**   
  AR                  0.307                          0.330                           0.045           588
                      ***P*=0.000**                  ***P*=0.000**                   *P*=0.279       

AR, androgen receptor; DHEAS, dehydroepiandrosterone sulfate; ER, estrogen receptor; SHBG, sex hormone-binding globulin.

###### 

Comparison of sex steroid hormones and sex steroid receptor serum bioactivity levels 6 months to 5 years before breast cancer diagnosis between cases and controls

                              **Controls**   **More than 2 years before breast cancer diagnosis**   **\<2 years before breast cancer diagnosis**   **All samples**                                                                                                                         
  --------------------------- -------------- ------------------------------------------------------ ---------------------------------------------- ----------------- ----- ------- -------- ------- ---------- ---- -------- -------- -------- ---------- ----- -------- -------- -------- ----------
  SHBG (μg/ml)                385            596.00                                                 560.53                                         274.63            100   555.7   502.21   224.8   0.50       95   510.95   489.95   215.68   **0.02**   195   533.36   500.53   220.84   0.12
  Testosterone (ng/ml)        382            0.28                                                   0.25                                           0.16              99    0.38    0.29     0.34    **0.01**   94   0.31     0.27     0.18     0.08       193   0.35     0.28     0.28     **0.04**
  Free testosterone (ng/dl)   365            0.12                                                   0.09                                           0.20              100   0.16    0.14     0.16    **0.03**   93   0.13     0.11     0.10     **0.03**   193   0.15     0.11     0.13     **0.00**
  Androstenedione (ng/dl)     386            96.85                                                  89.68                                          50.43             100   120.1   106.30   66.76   **0.00**   95   113.18   96.56    65.04    0.19       195   116.62   102.87   65.90    **0.01**
  DHEAS (μg/ml)               385            111.83                                                 100.6                                          61.15             100   116.5   93.90    75.31   1.00       95   121.3    103      70.78    0.25       195   118.87   97.95    72.92    0.58
  AR (ng/ml)                  391            2.33                                                   2.32                                           1.01              103   2.44    2.38     0.88    0.19       94   2.28     2.26     0.85     0.20       197   2.36     2.29     0.86     0.97
  Estradiol (E~2~; pg/ml)     379            18.44                                                  16.03                                          13.81             100   19.2    16.87    9.96    0.20       93   17.93    16.24    11.19    0.93       194   18.57    16.51    10.59    0.47
  Free E~2~ (pg/ml)           362            0.91                                                   0.79                                           0.62              100   1.00    0.84     0.57    0.17       93   0.93     0.84     0.44     0.17       193   0.98     0.84     0.51     0.07
  Estrone (pg/ml)             384            99.74                                                  80.93                                          80.63             103   108.7   81.16    118.2   0.46       95   116.56   83.14    132.79   0.09       198   112.42   81.79    125.44   0.11
  ERα (pg/ml)                 390            70.74                                                  62.09                                          60.45             103   85.60   74.85    67.19   **0.05**   95   74.86    57.60    69.81    0.78       198   80.24    64.17    68.54    0.30
  ERβ (pg/ml)                 391            59.95                                                  43.87                                          67.63             103   82.26   59.64    80.79   **0.01**   95   61.10    37.56    85.81    0.26       198   71.69    48.22    83.79    0.41

AR, androgen receptor; DHEAS, dehydroepiandrosterone sulfate; ER, estrogen receptor; SHBG, sex hormone-binding globulin; STD, standard deviation.

Numbers do not always add up to 200 cases and 400 controls due to some missing values.

Kruskal--Wallis for difference in median value between cases and controls.

###### 

Sex steroid receptor serum bioactivity (A) sex steroid hormones (B) and breast cancer risk

                                                           **Cases**                             **Cases**        **Cases**                                                                             
  ---------------------------- ----- ---------------- ---- ----------- ------------------------- ----------- ---- ----------- ------------------------- ----------- ---- ---- ------------------------- ------------
  \(A\) Serum bioactivity                                                                                                                                                                               
   ERα (pg/ml)                                                                                                                                                                                          
                               1st   0--27.06         77   14          1.00 (ref.)                           77   22          1.00 (ref.)                           77   36   1.00 (ref.)               
                               2nd   27.06--52.73     76   17          1.22 (0.56--2.68)         0.617       76   20          0.92 (0.46--1.83)         0.817       76   37   1.04 (0.593--1.816)       0.898
                               3rd   52.73--70.01     76   15          1.08 (0.48--2.41)         0.853       76   16          0.74 (0.36--1.50)         0.405       76   31   0.87 (0.484--1.538)       0.621
                               4th   70.01--104.36    76   20          1.49 (0.70--3.23)         0.306       76   21          0.97 (0.492--1.92)        0.935       76   41   1.16 (0.669--2.016)       0.598
                               5th   104.36--459.22   76   29          2.11 (1.05--4.43)         **0.040**   76   21          0.91 (0.46--1.81)         0.793       76   49   1.38 (0.807--2.360)       0.243
                                                                       *P* for trend=0.039                                    *P* for trend=0.854                             *P* for trend=0.304       
   ERβ (pg/ml)                 1st   0--2.97          77   13          1.00 (ref.)                           77   23          1.00 (ref.)                           77   36   1.00 (ref.)               
                               2nd   2.97--34.36      76   13          0.98 (0.42--2.23)         0.959       76   23          1.03 (0.53--1.99)         0.934       76   36   1.01 (0.57--1.78)         0.967
                               3rd   34.36--55.80     76   18          1.41 (0.65--3.13)         0.392       76   19          0.84 (0.42--1.67)         0.622       76   37   1.05 (0.60--1.83)         0.878
                               4th   55.80--98.96     76   25          1.95 (0.94--4.20)         0.079       76   20          0.87 (0.44--1.72)         0.692       76   45   1.27 (0.74--2.189)        0.387
                               5th   98.96--477.56    77   26          1.99 (0.97--4.27)         0.067       77   20          0.61 (0.29--1.27)         0.191       77   40   1.11 (0.641--1.93)        0.706
                                                                       *P* for trend=0.015                                    *P* for trend=0.227                             *P* for trend=0.565       
   AR (pg/ml)                  1st   0.36--1.59       77   17          1.00 (ref.)                           77   24          1.00 (ref.)                           77   41   1.00 (ref.)               
                               2nd   1.59--2.10       76   10          0.60 (0.25--1.37)         0.231       76   18          0.76 (0.38--1.51)         0.441       76   28   0.69 (0.39--1.23)         0.212
                               3rd   2.10--2.45       76   23          1.38 (0.68--2.81)         0.374       76   25          1.06 (0.56--2.02)         0.863       76   48   1.19 (0.71--2.02)         0.509
                               4th   2.45--2.87       76   21          1.26 (0.62--2.59)         0.533       76   12          0.50 (0.23--1.05)         0.074       76   33   0.81 (0.47--1.42)         0.47
                               5th   2.87--7.45       77   23          1.38 (0.68--2.82)         0.375       77   12          0.84 (0.42--1.64)         0.604       77   43   1.06 (0.62--1.82)         0.824
                                                                       *P* for trend=0.110                                    *P* for trend=0.310                             *P* for trend=0.744       
  \(B\) Hormone                                                                                                                                                                                         
   Estradiol (E~2~; pg/ml)     1st   0--11.47         76   16          1.00 (ref.)                           76   20          1.00 (ref.)                           76   36   1.00 (ref.)               
                               2nd   11.47--14.74     75   13          0.84 (0.37--1.88)         0.677       75   16          0.81 (0.39--1.69)         0.578       75   29   0.82 (0.46--1.48)         0.514
                               3rd   14.74--17.98     75   22          1.39 (0.68--2.90          0.366       75   25          1.29 (0.66--2.57)         0.453       75   47   1.33 (0.78--2.29)         0.304
                               4th   17.98--22.66     75   20          1.27 (0.61--2.67)         0.522       75   20          1.02 (0.50--2.05)         0.965       75   40   1.12 (0.65--1.95)         0.685
                               5th   22.66--209.40    75   23          1.46 (0.72--3.03)         0.298       75   20          0.91 (0.44--1.86)         0.799       75   41   1.15 (0.67--2.00)         0.613
                                                                       *P* for trend=0.141                                    *P* for trend=0.973                             *P* for trend=0.304       
   Free E~2~ (pg/ml)           1st   0--0.50          76   14          1.00 (ref.)                           76   13          1.00 (ref.)                           76   27   1.00 (ref.)               
                               2nd   0.50--0.69       75   15          1.07 (0.48--2.40)         0.861       75   17          1.20 (0.67--2.21)         0.546       75   32   1.32 (0.60--2.96)         0.546
                               3rd   0.69--0.90       75   27          1.95 (0.96--4.10)         0.071       75   28          2.08 (1.19--3.68)         0.017       75   55   2.19 (1.07--4.67)         0.011
                               4th   0.90--1.19       75   15          1.10 (0.49--2.46)         0.821       75   19          1.30 (0.71--2.37)         0.399       75   34   1.50 (0.70--3.33)         0.399
                               5th   1.19--6.62       75   23          1.66 (0.80--3.54)         0.180       75   19          1.69 (0.96--3.03)         0.075       76   45   1.70 (0.81--3.71)         0.075
                                                                       *P* for trend=0.225                                    *P* for trend=0.169                             *P* for trend=0.073       
   Estrone (pg/ml)             1st   0--56.28         76   14          1.00 (ref.)                           76   14          1.00 (ref.)                           76   28   1.00 (ref.)               
                               2nd   56.28--72.63     75   23          1.65 (0.78--3.52)         0.183       75   17          1.24 (0.57--2.75)         0.583       75   40   1.44 (0.81--2.59)         0.218
                               3rd   72.63--90.14     75   22          1.58 (0.76--3.39)         0.229       75   19          1.35 (0.63--2.95)         0.437       75   41   1.46 (0.82--2.62)         0.202
                               4th   90.14--115.53    75   15          1.07 (0.48--2.436)        0.862       75   19          1.33 (0.62--2.89)         0.472       75   34   1.20 (0.66--2.19)         0.559
                               5th   115.53--779.83   75   21          1.53 (0.73--3.31)         0.267       75   19          2.21 (1.10--4.59)         **0.029**   76   52   1.86 (1.07--3.29)         **0.030**
                                                                       *P* for trend=0.624                                    *P* for trend=0.062                             *P* for trend=0.122       
   Androstenedione (ng/dl)     1st   0--52.44         76   7           1.00 (ref.)                           76   12          1.00 (ref.)                           76   19   1.00 (ref.)               
                               2nd   52.44--77.94     76   18          3.09 (1.23--8.65)         **0.022**   76   23          2.18 (1.01--4.95)         0.054       76   41   2.52 (1.33--4.95)         **0.006**
                               3rd   77.94--102.87    74   17          2.84 (1.13--7.88)         **0.033**   74   18          1.57 (0.71--3.60)         0.271       74   35   2.02 (1.06--3.94)         **0.036**
                               4th   102.87--132.09   75   23          3.64 (1.51--9.84)         **0.006**   75   13          1.09 (0.46--2.61)         0.845       75   36   2.01 (1.06--3.94)         **0.037**
                               5th   132.09--383.95   76   30          4.36 (1.87--11.55)        **0.001**   75   13          2.49 (1.20--5.46)         **0.018**   76   60   3.19 (1.74--6.04)         **0.0003**
                                                                       ***P* for trend=0.001**                                *P* for trend=0.310                             ***P* for trend=0.007**   
   Testosterone (ng/ml)        1st   0--0.16          77   13          1.00 (ref.)                           77   18          1.00 (ref.)                           77   31   1.00 (ref.)               
                               2nd   0.16--0.22       75   15          1.22 (0.54--2.80)         0.636       75   19          1.15 (0.55--2.39)         0.714       75   34   1.16 (0.65--2.10)         0.613
                               3rd   0.22--0.29       75   18          1.38 (0.63--3.10)         0.427       75   18          1.02 (0.48--2.13)         0.969       75   36   1.17 (0.65--2.10)         0.590
                               4th   0.29--0.38       76   15          1.19 (0.53--2.72)         0.669       76   9           0.49 (0.20--1.13)         0.104       76   24   0.78 (0.42--1.45)         0.441
                               5th   0.38--1.07       76   33          2.53 (1.24--5.41)         **0.013**   76   9           1.87 (0.97--3.68)         **0.05**    76   68   2.15 (1.26--3.71)         **0.006**
                                                                       ***P* for trend=0.011**                                *P* for trend=0.087                             ***P* for trend=0.005**   
   Free testosterone (ng/dl)   1st   0--0.05          79   10          1.00 (ref.)                           79   14          1.00 (ref.)                           79   24   1.00 (ref.)               
                               2nd   0.05--0.08       76   18          1.93 (0.845--4.62)        0.126       76   24          1.81 (0.88--3.86)         0.112       76   42   1.85 (1.03--3.38)         0.044
                               3rd   0.08--0.11       74   18          1.96 (0.86--4.67)         0.115       74   12          0.92 (0.39--2.12)         0.843       74   30   1.34 (0.72--2.53)         0.355
                               4th   0.11--0.16       75   22          2.26 (1.02--5.29)         0.050       75   20          1.51 (0.72--3.26)         0.283       75   42   1.83 (1.02--3.35)         0.046
                               5th   0.16--3.48       76   26          2.84 (1.30--6.64)         **0.011**   75   20          2.02 (0.99--4.24)         0.057       76   55   2.35 (1.33--4.26)         **0.004**
                                                                       ***P* for trend=0.013**                                *P* for trend=0.078                             ***P* for trend=0.007**   
   DHEAS (μg/ml)               1st   0--58.44         77   17          1.00 (ref.)                           77   16          1.00 (ref.)                           77   33   1.00 (ref.)               
                               2nd   58.44--85.52     77   22          1.29 (0.64--2.66)         0.483       77   15          0.96 (0.44--2.09)         0.92        77   37   1.14 (0.65--2.02)         0.654
                               3rd   85.52--119.16    76   24          1.44 (0.71--2.98)         0.312       76   28          1.79 (0.89--3.70)         0.106       76   52   1.62 (0.93--2.84)         0.089
                               4th   119.16--162.04   77   14          1.05 (0.45--2.44)         0.908       77   20          1.58 (0.72--3.55)         0.26        77   34   1.31 (0.70--2.47)         0.396
                               5th   162.04--459.60   77   18          1.40 (0.60--3.28)         0.438       77   20          1.53 (0.65--3.64)         0.325       77   39   1.49 (0.77--2.90)         0.237
                                                                       *P* for trend=0.695                                    *P* for trend=0.341                             *P* for trend=0.838       
   SHBG (μg/ml)                1st   0--346.53        77   15          1.00 (ref.)                           77   25          1.00 (ref.)                           77   40   1.00 (ref.)               
                               2nd   346.15--485.79   77   30          1.99 (1.00--4.09)         0.053       77   20          0.81 (0.41--1.57)         0.53        77   50   1.24 (0.734--2.10)        0.418
                               3rd   485.79--634.32   76   17          1.15 (0.54--2.49)         0.722       76   31          1.26 (0.68--2.36)         0.459       76   48   1.22 (0.72--2.07)         0.46
                               4th   634.32--843.47   77   22          1.48 (0.72--3.11)         0.295       77   16          0.65 (0.3127--1.30)       0.228       77   38   0.96 (0.56--1.67)         0.891
                               5th   843.47--1533.7   77   11          0.71 (0.30--1.64)         0.422       77   16          0.32 (0.13--0.73)         **0.001**   77   19   0.48 (0.25--0.89)         **0.022**
                                                                       *P* for trend=0.290                                    ***P* for trend=0.015**                         ***P* for trend=0.004**   

OR values for quintiles based on controls only being age adjusted. OR with *P* values ≤0.05 marked with bold. AR, androgen receptor; DHEAS, dehydroepiandrosterone sulfate; ER, estrogen receptor; OR, odds ratio; SHBG, sex hormone-binding globulin.
